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Edited by Varda RotterAbstract Indole-3-carbinol (I3C) is a naturally occurring
compound found in vegetables such as broccoli and cauliﬂower,
and has been shown to arrest human tumor cells in the G1 phase
of the cell cycle. However, the molecular mechanism responsible
for this eﬀect has not been suﬃciently elucidated. We report here
that I3C activates the cyclin-dependent kinase (CDK) inhibitor
p15INK4b gene through its promoter, accompanied by cell growth
inhibition in HaCaT cells. Treatment with I3C almost did not
aﬀect the expressions of the other CDK inhibitors such as
p19INK4d, p21WAF1 and p27Kip1. These results suggest that
p15INK4b is an important molecular target of I3C among CDK
inhibitors.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cell-cycle progression is regulated by proteins called cyclins
and cyclin-dependent kinases (CDKs) that associate with each
other [1]. The process of cyclin-dependent activation of CDKs
is counterbalanced by CDK inhibitors [2]. Two families of
CDK inhibitors were identiﬁed in mammalian cells and each
has a diﬀerent mode of action. One group, comprised of re-
lated proteins known as p21WAF1, p27Kip1 and p57Kip2, inhibit
cyclin E/A-CDK2 complexes [3]. The second family of CDK
inhibitors is also called INK4 protein family, and its members,
designated p15INK4b, p16INK4a, p18INK4c and p19INK4d, directly
bind to CDK4/6 and are speciﬁc inhibitors of cyclin D-de-
pendent kinases [4–6].
Indole-3-carbinol (I3C) is a naturally occurring compound
found in vegetables of the Brassica genus such as broccoli,
brussel sprouts and cauliﬂower [7,8]. When administered in the
diet, I3C signiﬁcantly decreases the incidence of spontaneous
and chemically induced mammary tumors in mice [9,10]. I3C
exerts antiproliferative activity in human cancer cells and in-
hibits cell adhesion, migration and invasion [11].* Corresponding author. Fax: +81-75-241-0792.
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doi:10.1016/j.febslet.2004.09.002I3C induces cell-cycle arrest in the G1 phase [12–14]. How-
ever, the molecular mechanism responsible for this eﬀect has
not been suﬃciently elucidated. We therefore examined the
eﬀect of I3C on the expressions of CDK inhibitors in human
immortalized keratinocyte HaCaT cells. We show that I3C
activates the CDK inhibitor p15INK4b gene through its pro-
moter, accompanied by cell growth inhibition. Treatment with
I3C almost did not aﬀect the expression of other CDK in-
hibitors such as p19INK4d, p21WAF1 and p27Kip1. These results
suggest that p15INK4b is an important molecular target of I3C
among CDK inhibitors.2. Materials and methods
2.1. Cell culture and reagents
HaCaT cells (a gift from Dr. N.E. Fusenig, German Cancer Re-
search Center, Heidelberg, Germany) were maintained in DMEM
containing 10% fetal bovine serum and 2 mM glutamine and antibi-
otics (penicillin/streptomycin), and were incubated at 37 C in a hu-
midiﬁed atmosphere with 5% CO2. I3C (Wako, Osaka, Japan) was
dissolved in dimethyl sulfoxide (DMSO).
2.2. Analysis of cell-cycle progression
Unsynchronized HaCaT cells were exposed to I3C for 48 h. The cells
were then treated with Triton X-100 and their nuclei were stained with
propidium iodide before DNA content was measured using a Becton
Dickinson FACS Calibur (Becton Dickinson, Mountain view, CA). At
least 10 000 cells were counted and the ModFit LD V2.0 software
package (Becton Dickinson, Franklin Lakes, NJ) was used to analyze
the data.
2.3. Detection of apoptosis
Unsynchronized HaCaT cells were exposed to I3C for 48 or 72 h.
The cells were then treated with Triton X-100 and their nuclei were
stained with propidium iodide before DNA content was measured
using a Becton Dickinson FACS Calibur (Becton Dickinson). At least
10 000 cells were counted and the ModFit LD V2.0 software package
(Becton Dickinson) was used to analyze the data. DNA fragmentation
was quantiﬁed by the percentage of cells with hypodiploid DNA (sub-
G1).
2.4. Protein isolation and Western blot analysis
Cells were lyzed in lysis buﬀer (50 mM Tris–HCl (pH 7.5), 1% SDS).
The protein extract was then boiled for 5 min and loaded onto a 12%
(for p15INK4b, p19INK4d, p21WAF1, p27Kip1 and CDK6 detection) or 7%
(for RB detection) polyacrylamide gel, electrophoresed and transferred
to a nitrocellulose membrane. Rabbit anti-human p15INK4b polyclonal
antibody (pAb) (C-20, Santa Cruz Biotechnology, CA), mouse anti-
human p19INK4d mAb (DCS-100, NeoMarkers, Union City, CA),
mouse anti-human p21Cip1=Waf1 mAb (clone 6B6, Pharmingen, NJ),blished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of I3C on the growth and cell cycle of HaCaT cells. (A)
One day after inoculation of HaCaT cells, I3C at 200, 300, 400 or 500
lM was added, and cell growth was compared with a control cell
culture with equivalent DMSO. The number of viable cells was
counted by the Trypan-blue dye exclusion test. (B) Unsynchronized
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CA), mouse anti-human CDK6 mAb (DCS-83, MBL, Nagoya, Japan)
and mouse anti-human pRB mAb (clone G3-245, Pharmingen) were
used as the primary antibody. The signal was then developed with an
enhanced chemiluminescence system (Amersham Pharmacia Biotech,
UK Limited).
2.5. RNA isolation and Northern blot analysis
Total RNA was isolated using a Sepasol RNA isolation kit (Nacalai
Tesque Inc., Kyoto, Japan) and poly (A)þ mRNA was separated from
100 lg of total RNA using an OligotexTM-dT30 hSuperi mRNA pu-
riﬁcation kit (Takara Bio Inc., Shiga, Japan). Poly (A)þ mRNA was
fractionated on 1% agarose gels, transferred to nylon ﬁlters, and
probed according to standard procedures [15]. Exon 1 of p15 cDNA
was used as a probe. Northern blot analysis was performed using
standard methods [15] and mRNA levels were determined using a Fuji
Image Analyzer Bas 2000 (Fujix, Tokyo, Japan).
2.6. Transient transfection and luciferase assay
The p15INK4b-luciferase fusion plasmid [16] was co-transfected with
pRL-TK (Promega, WI, USA) for standardization by Renilla lucif-
erase activity. For each 24-well culture plate, HaCaT cells (5 104
cells) were transfected with 0.816 lg of DNA (0.8 lg of p15INK4b-
luciferase fusion plasmid and 0.016 lg of pRL-TK) using Lipofectin
reagents (Invitrogen, Groningen, Netherlands). After 22 h, I3C was
added, and 46 h after transfection the cells were harvested. The
luciferase activity of each cell lysate was measured using a Dual-
Luciferase Reporter Plasmid System (Promega, WI). The ﬁreﬂy
luciferase activity of each sample was normalized by its Renilla lu-
ciferase activity and the fold activation was obtained by setting the
control value to 1.0. All transfection assays were carried out in
triplicate. The data are shown as the meansS.D., and were ana-
lyzed using the Student’s t-test. A P-value of less than 0.05 was
considered to be statistically signiﬁcant.cells were incubated in the presence of DMSO or 400 lM I3C for 48 h,
and the DNA content of the cells was determined by ﬂow cytometry.3. Results
3.1. I3C induces growth arrest in the G1 phase in HaCaT cells
We ﬁrst examined the eﬀect of I3C on the proliferation of
human immortalized keratinocyte HaCaT cells. I3C inhibited
the proliferation of HaCaT cells in a dose-dependent manner
and 400 lM I3C had a cytostatic eﬀect (Fig. 1A). To investi-
gate the eﬀect of I3C on cell-cycle progression, the DNA
content of cell nuclei was measured by ﬂow cytometric anal-
ysis. Treatment with I3C increased the percentage in the G1
phase, and decreased that in the S phase (Fig. 1B). This shows
that I3C arrests the cell cycle of HaCaT cells at the G1 phase.
Furthermore, 500 lM of I3C reduces the number of HaCaT
cells within 3–4 days of the treatment. To examine whether I3C
induces apotosis in these cells, we detected Sub-G1 popula-
tions (apoptotic cells) using ﬂow cytometry analysis. Treat-
ment with I3C (500 lM) for 3 days had no eﬀect on Sub-G1
populations compared to vehicle only (data not shown).
However, 500 lM of I3C for 4 days induced a signiﬁcant in-
crease of Sub-G1 populations (48%) compared to that with
vehicle only (4%). This result shows that high concentrations
of I3C induce apoptosis in HaCaT cells.
3.2. I3C increases p15INK4b mRNA and protein levels in HaCaT
cells
We investigated whether I3C aﬀects p15INK4b gene expres-
sion in HaCaT cells and found that I3C stimulates the ex-
pression of p15INK4b mRNA in a dose-dependent manner
(Fig. 2A). The longer transcript is about 3.2 kb and the shorter
one is about 2.2 kb. These two transcripts are detected in a
previous report [4]. This is consistent with the result that I3C
inhibited the growth of HaCaT cells in a dose-dependentmanner (Fig. 1A). The time course study indicated that
p15INK4b mRNA was up-regulated 12 h after treatment with
I3C (Fig. 2B). Maximal induction was attained 36 h after
treatment (Fig. 2B).
Next, we tried to elucidate whether the expression of
p15INK4b protein could also be induced by treatment with I3C
in HaCaT cells. We found that treatment stimulated p15INK4b
protein expression in a dose-dependent manner (Fig. 2C). The
time course study showed that expression was signiﬁcantly
increased 24 h after treatment (Fig. 2D). The eﬀect of I3C on
p15 protein reaches a peak 36 h after treatment, and declined
at 48 h (Fig. 2D). This suggests that activation of p15 gene
expression by I3C may decrease or p15 protein may degrade 48
h after treatment with I3C.
p15INK4b is a speciﬁc inhibitor of cyclin D-dependent kinases
and the subsequent dephosphorylation of RB protein causes
G1 arrest [4]. Therefore, we examined whether I3C can alter
the phosphorylation status of RB protein in HaCaT cells by
Western blotting. A hyperphosphorylated form of RB protein
was converted into a hypophosphorylated form 24–36 h after
treatment (Fig. 2E).
Taken together, these results indicate that I3C upregulates
p15INK4b mRNA and protein levels and, subsequently, a hy-
perphosphorylated form of the RB protein is converted into a
hypophosphorylated form in HaCaT cells.
3.3. I3C activates p15INK4b promoter activity in HaCaT cells
Since we found that p15INK4b mRNA expression is induced
by I3C in HaCaT cells, we investigated whether I3C activates
the promoter activity of the p15INK4b gene. Treatment with
I3C activated the promoter activity in a dose-dependent
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Fig. 3. Activation of p15INK4b promoter activity in HaCaT cells by
treatment with I3C. HaCaT cells were transiently transfected with the
p15INK4b–luciferase fusion plasmid, and luciferase activities were
measured after incubation in medium containing various concentra-
tions of I3C for 24 h. The data are shown as the meansS.D.
ðn ¼ 3Þ: ; P < 0:05.
Fig. 2. Northern blot analysis of p15INK4b mRNA and Western blot
analysis of p15INK4b or RB protein in HaCaT cells. (A,B) HaCaT cells
were treated with various concentrations of I3C for 24 h (A) or 400 lM
I3C for the indicated times (B), and the expression of p15INK4b mRNA
was examined. The mRNA level of p15INK4b was standardized against
that of glyceraldehyde-3-phosphate dehydrogenase. (C) HaCaT cells
were treated with various concentrations of I3C, and the expression of
p15INK4b protein was examined after 24 h exposure to I3C. a-Tubulin
(Oncogene Research Product, CA) was chosen as a loading control for
all Western blots. (D,E) HaCaT cells were exposed to DMSO alone ())
or 400 lM I3C (+) for the indicated times. The expressions of p15INK4b
(D) and RB proteins (E) were detected. Data shown below the blot (D)
represent fold induction in the p15INK4b protein expression quantiﬁed
by densitometer analysis (Kodak 1D 2.0.2 Image Analysis Software,
USA), and each value was compared with that of the control (0 h)
which was estimated as 1.0.
Fig. 4. Eﬀect of I3C on the expressions of p15INK4b, p19INK4d,
p21WAF1, p27Kip1 and CDK6 in HaCaT cells by Western blotting.
HaCaT cells were exposed to DMSO ()) or 400 lM I3C (+) for the
indicated times.
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p15INK4b promoter activity in HaCaT cells.
3.4. Eﬀect of I3C on the expressions of other CDK inhibitors in
HaCaT cells
We examined the eﬀect of I3C on the expressions of other
CDK inhibitors in HaCaT cells by Western blotting. The
abundance of p19INK4d, p21WAF1 and p27Kip1 was almost un-
changed by treatment with I3C (Fig. 4). We could not detect
the expression of p16INK4a in HaCaT cells (data not shown).
Furthermore, we could not evaluate the eﬀect of I3C on
p18INK4c protein expression due to weak band and high
background in the Western blotting (data not shown). There-
fore, these results suggest that p15INK4b is an important mo-
lecular target of I3C among CDK inhibitors.Finally, we examined the eﬀect of I3C on the expression of
CDK6 in HaCaT cells. It has been shown that the treatment
with I3C decreases the expression of CDK6 in human breast
cancer cells [12]. As shown in Fig. 4, the time course study
indicated that CDK6 protein was down-regulated 18 h after
treatment with I3C in HaCaT cells.4. Discussion
Our results indicate that I3C arrests the cell cycle of HaCaT
cells in the G1 phase and inhibits cell growth. Furthermore,
I3C stimulates p15INK4b promoter activity and upregulates
p15INK4b mRNA and protein levels, and that the hyper-
phosphorylated form of the RB protein is converted into a
hypophosphorylated form in HaCaT cells. However, treat-
ment with I3C almost did not aﬀect the expressions of other
CDK inhibitors such as p19INK4d, p21WAF1 and p27Kip1. Taken
140 Y. Matsuzaki et al. / FEBS Letters 576 (2004) 137–140together, these results suggest that p15INK4b is an important
molecular target of I3C among CDK inhibitors.
We recently examined the eﬀect of ectopic p15INK4b ex-
pression on the growth of HaCaT cells by selecting for Ge-
neticin resistant cells after transfection with p15INK4b
expression vectors encoding the p15INK4b and neomycin re-
sistance genes [16]. The recovery of antibiotic-resistant HaCaT
cells was markedly inhibited by the ectopic expression of
p15INK4b, suggesting that this gene inhibits cellular growth in
HaCaT cells [16]. Thus, activation of the p15INK4b gene may
contribute to growth arrest induced by I3C.
It has been shown that the treatment with I3C decreases the
expression of CDK6 in human breast cancer cells [12]. In this
study, we observed that the expression of CDK6 is down-
regulated by I3C in HaCaT cells. Taken together with our
result that the expression of p15INK4b, a speciﬁc inhibitor of
CDK4/6, is up-regulated by I3C, it is suggested that cyclin D-
CDK6 activity is inhibited by I3C through dual mechanisms in
HaCaT cells.
We previously showed that butyrate inhibits cellular pro-
liferation and induces the p15INK4b gene through its pro-
moter in HaCaT cells [16]. Butyrate is one of the most
abundant short chain fatty acids in the large intestine, and is
generated by the bacterial fermentation of dietary ﬁbers [17].
It also has anti-tumor properties in vivo and in vitro at
physiological concentrations, suggesting that it may have
preventive eﬀects against large bowel cancer [18–20]. We
examined whether combination treatment with I3C and bu-
tyrate is more eﬃcacious for growth inhibition than either
agent alone. Simultaneous treatment with I3C and butyrate
enhanced growth inhibition in HaCaT cells (data not
shown).
The inactivation of p16INK4a has been extensively reported
for most human malignant tumors [21]. As a member of the
INK4 family, p15INK4b has a function similar to that of
p16INK4a. This suggests that p15INK4b may function as a
replacement for p16INK4a when p16INK4a is inactivated.
Aytac et al. [22], recently showed that p15INK4b inhibits
cellular proliferation independent of RB. The ectopic ex-
pression of p16INK4a inhibits the growth of cell lines de-
pending on RB status [22]. However, in the case of
p15INK4b, cellular proliferation was inhibited in cells lacking
RB as well as in cells exhibiting wild-type RB expression.
Therefore, transcriptionally up-regulated agents of the
p15INK4b gene may contribute to new strategies for the
prevention or therapy of malignancies, which we term ‘gene-
regulating chemoprevention or chemotherapy’ [23–25]. I3C,
which activates p15INK4b gene expression, might be repre-
sentative of gene-regulating chemopreventive or chemother-apeutical agents over a broad spectrum of tumors regardless
of RB status.
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